Video: Boston doctor breaks down new COVID-19 vaccine data from Moderna
Updated: 6:41 PM EDT Jun 22, 2022
AS COVID-19 CONTINUES TO EVOLVE, EVOLVE WITH IT. AND TONIGHT, MODERNA IS OUT WITH SOME NEW DATA ABOUT THE NEXT STAGE OF THE FIGHT AGAINST THIS VIRUS. JOINING US FOR SOME IMPORTANT INSIGHT IS DR. DANIEL KURITZKES, AN INFECTIOUS DISEASE SPECIALIST AT BRIGHAM AND WOMEN’S HOSPITAL. DR. KURITZKES, THANKS FOR BEING HERE. BEN: CAMBRIDGE-BASED MODERNA SAYS ITS NEW OMICRON-TARGETING VACCINE IS SHOWING SOME SUCCESS AGAINST THE NEWEST SUBVARIANTS. BUT, THE IMMUNE RESPONSE WASN’T AS STRONG, IS THAT A CONCERN? >> I’M NOT TOO CONCERNED. IT SHOWS THE CHALLENGES TRYING TO FIND WHICH VARIANT IS THE BEST ONE TO PUT INTO A NEW VACCINE. THIS VACCINE IS BASED ON THE BA1 VARIANT. NOW WE’RE SEEING BA4 AND 5. IT’S STILL BOOST IMMUNE RESPONSES AGAINST BA4 AND 5, IT’S NOT QUITE BOOST RESPONSES FOR BA1. ERIKA: THE VIRUS IS MUTATING. STILL TRYING TO FIND WAYS TO SPREAD. WE SHOULD EXPECT NEW SHOTS? HOW DO YOU THINK IT’S REALISTIC TO EXPECT A NEW FORMULA? >> I DON’T THINK WE’LL SEE NEW FORMULAS MORE FREQUENTLY ONCE EVERY YEAR. IT TAKES SO LONG TO PUT THESE THINGS TOGETHER. IT WILL BE REASONABLE TO ANTICIPATE THEM. WE’VE BEEN SEEING A NEW VARIANT EMERGE EVERY 4 TO 5 MONTHS. I WILL BE SURPRISED IF THAT DOESN’T CONTINUE FOR SOME TIME. BEN: AND TO OUR VIEWERS IF YOU
Advertisement
Video: Boston doctor breaks down new COVID-19 vaccine data from Moderna
Updated: 6:41 PM EDT Jun 22, 2022
Cambridge-based Moderna says its new omicron-targeting vaccine is showing some success against the new subvariants, but the immune response was not as strong.
Cambridge-based Moderna says its new omicron-targeting vaccine is showing some success against the new subvariants, but the immune response was not as strong.
Advertisement